SEC Tracker
Get the app

Selecta Biosciences RNAC

Selecta Biosciences appoints Blaine Davis as Chief Financial Officer

Form
8-K
Filed
Period
Importance
Major
Document
8-K
Exhibit 99.1
Press release
  • Reports an executive or board change (5.02)
  • Makes a Regulation FD disclosure (7.01)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Selecta Biosciences files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Galectin Therapeutics GALT public float $109M, Jun 30, 2025
  2. Atossa Therapeutics ATOS public float $107M, Jun 30, 2025
  3. Enanta Pharmaceuticals ENTA public float $111M, Mar 31, 2025, over 18 months old
  4. TuHURA Biosciences HURA public float $111M, Jun 30, 2025
  5. Fennec Pharmaceuticals FENC public float $106M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.